Exploring Rab 32 Gene Variations in Leprosy Patients
Official title: Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multiple Drug Therapy: Randomized Clinical Trial
Run by South Valley University · NCT06819449 · Data updated 2026-11-12
This study is trying to see if differences in a specific gene can help predict how leprosy patients will respond to treatment and how severe their disease might be.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 5 Years to 60 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | South Valley University Academic / other |
| Locations | 1 site (Qina) |
| Status | Recruiting |
| Started | December 20, 2024 |
| Main results expected | December 10, 2025 |
| Study ends | December 20, 2025 |
| Registry record updated | February 11, 2025 |
| Trial ID | NCT06819449 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients of both sexes with a positive slit skin smear for Mycobacterium leprae.
✕Probably not a fit
Patients with hypersensitivity to sulfa drugs, clofazimine, or rifampicin, as well as pregnant or lactating women, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the role of Rab 32 gene polymorphisms as a potential prognostic factor in patients suffering from leprosy, caused by the Mycobacterium leprae bacterium. It aims to understand how these genetic variations may influence the disease's progression and response to treatment. The study will involve patients with confirmed leprosy, who will be treated with standard multi-drug therapy, including dapsone. By analyzing the genetic profiles of these patients, researchers hope to identify markers that could predict treatment outcomes and disease severity.
Why it matters
Potential benefit: If successful, this study could lead to improved prognostic tools for leprosy patients, allowing for more personalized treatment strategies.
How similar studies have gone: While the specific approach of examining Rab 32 gene polymorphisms in leprosy is novel, similar genetic studies in other infectious diseases have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of both sexes with positive slit skin smear for m.leprae . Exclusion Criteria: * Contraindications to Multi drug therapy : * Patients with hypersensitivity to sulfa . * Patients with hypersensitivity to clofazimine or rifampcin. * pregnant or lactating women.
Where it's running
-
Qina University hospital, South Valley University Hospital
Qina, Egypt Recruiting
Study contacts
- Study coordinator: Lydia Atef Nassief, MSc
- Email: lydiaatef67@gmail.com
- Phone: +201289416276
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ultrasound-guided ulnar nerve PCR test to diagnose and monitor leprosy
This test uses an ultrasound-guided needle sample from the ulnar nerve combined with PCR to see if it can detect Mycobacterium leprae and help diagnose or monitor people with suspected or confirmed leprosy.
-
New methods for diagnosing and preventing leprosy
This study is testing new ways to find and prevent leprosy in people who have been close to someone diagnosed with it, using a single-dose antibiotic and a new test to spot the disease early.
-
Bedaquiline for preventing leprosy after exposure
This study is testing if a new treatment called Bedaquiline can better prevent leprosy in people living close to someone who has the disease compared to the usual medication.
-
Using metformin to improve treatment for multibacillary leprosy
This study is testing if adding metformin to the standard treatment for newly diagnosed multibacillary leprosy can help reduce complications and improve safety for patients.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.